Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ANI Pharmaceuticals Inc

ANIP ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$74.17

▼ -1.57%

Market Cap $1.70B · Vol 107.02K

Key Metrics

P/E Ratio

16.08

FWD: 7.39

Market Cap

$1.70B

Small Cap

Div Yield

N/A

EPS Growth

+17.82%

YoY

RSI (14)

37.81

Momentum

Beta

0.45

vs Market

52W High

$99.45

25.42% below

52W Low

$70.15

5.73% above

Volume

107.02K

Avg 112.57K

P/B

3.28

Price-to-book

ROE

34.33%

Return on equity

Free Float

88.34%

Public shares

Shariah Compliance8 STANDARDS

✗ ANI Pharmaceuticals Inc (ANIP) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ANIP pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.41%

-4.48%

-10.34%

-3.30%

YTD

-6.04%

-18.50%

+16.24%

+155.76%

Financials & Valuation

TTM · Annual

Total Revenue	$883.37M
Net Income	$78.34M
Revenue Growth (YoY)	+25.87%
Gross Margin	51.01%
Operating Margin	9.43%
Net Profit Margin	8.87%
ROE	34.33%
ROA · ROIC	7.03% · 8.57%

P/E Ratio	16.08
Forward P/E (FY1)	7.39
PEG Ratio	0.06
P/S	1.90
P/B	3.28
P/FCF	11.10
EPS Growth	+17.82%
Outstanding Shares	22.97M

Technical Indicators

50-Day SMA	$80.16
200-Day SMA	$79.97
RSI (14)	37.81
Beta	0.45
52-Week High	$99.45
52-Week Low	$70.15

Volume Today	107.02K
Avg Daily Volume (30D)	112.57K
Relative Volume	0.95x
Volatility (10D)	23.71
Volatility (30D)	31.61
Free Float	88.34%

Analyst Consensus

BUY

Current Price $74.17

Mean Target $107.43

52W Low$70.15 52W High$99.45

Current

Target

$70.15 $99.45

Current Analyst target

+44.84% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S9DR85

ISINUS00182C1036

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 5, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -0.67% JNJ Johnson & Johnson +1.04% ABBV Abbvie Inc -0.17% NVS Novartis AG -0.53% NOVN.S Novartis AG -0.52%

Company Profile

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units, Rare Disease and Brands. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel and ILUVIEN. The Brands unit includes a portfolio of over 20 branded products that are principally sold in genericized markets. Its Generics and Other segment consists of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.